Trial Results Search
Clinical Trial Results: Tarceva [erlotinib]
-
Protocol Number: MO17156
Product Name: Tarceva [erlotinib]
Date of Report: 15.12.2008
Phase: II
-
Protocol Number: MO17654
Product Name: Tarceva [erlotinib]
Date of Report: 01.12.2008
Phase: II
-
Protocol Number: BO18279
Product Name: Tarceva [erlotinib]
Date of Report: 01.03.2008
Phase: II
A phase II marker identification trial for erlotinib (Tarceva) in second line NSCLC patients
-
Protocol Number: MO17426
Product Name: Tarceva [erlotinib]
Date of Report: 29.05.2008
Phase: II
-
Protocol Number: BO16411
Product Name: Tarceva [erlotinib]
Date of Report: 31.03.2004
Phase: III
-
Protocol Number: TOC4603g
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
-
Protocol Number: ML21869
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
-
Protocol Number: BO25460
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: III
-
Protocol Number: ML25637
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
-
Protocol Number: ML27880
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: IV
-
Protocol Number: ML25514
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
-
Protocol Number: ML25478
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: IV
-
Protocol Number: ML25575
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: IV
-
Protocol Number: ML25434
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
-
Protocol Number: ML25423
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
-
Protocol Number: MO22162
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: III
-
Protocol Number: YO25121
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: III
-
Protocol Number: ML25200
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
-
Protocol Number: ML25279
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
-
Protocol Number: ML23023
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: IV
-
Protocol Number: ML27895
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: IV
-
Protocol Number: ML28282
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: IV
-
Protocol Number: ML22973
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: IV
An Observational Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer
-
Protocol Number: ML27773
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: IV
-
Protocol Number: ML21474
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: IV
-
Protocol Number: ML22816
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: IV
-
Protocol Number: ML23024
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: IV
-
Protocol Number: ML25708
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: IV
-
Protocol Number: ML27860
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: III
-
Protocol Number: ML28361
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: IV
-
Protocol Number: ML28195
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: IV
About This Database
This database is populated with information on the results of Roche-sponsored clinical trials.